Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01802073 · ClinicalTrials.gov registry record · Phase 3
Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects
A Phase 3 study of Primary Sclerosing Cholangitis, sponsored by Stanford University.
- Completed
- Registry status
- Phase 3
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT01802073 is a Phase 3 study of Primary Sclerosing Cholangitis that has completed, run by Stanford University. The registered enrollment target is 34 participants, below the 551-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01802073, a Phase 3 study of Primary Sclerosing Cholangitis, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.
Conditions Studied
Interventions
- DRUG Oral Vancomycin
Study Locations (1)
California
- Stanford University Medical Center - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2012-01 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01802073
The ClinicalTrials.gov registry entry for NCT01802073 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 551-participant average among 23 other Primary Sclerosing Cholangitis trials with a reported enrollment target (94% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Sclerosing Cholangitis appearing as the primary indexed condition, and to 1 intervention - of which Oral Vancomycin is the first listed.
NCT01802073 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01802073 about?
NCT01802073 is a clinical study titled "Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects". Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.
What is the current status of trial NCT01802073?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 34 participants. The study started on 2012-01. Estimated completion is 2015-08.
What conditions does trial NCT01802073 study?
This clinical trial studies the following conditions: Primary Sclerosing Cholangitis.
What interventions are being tested in trial NCT01802073?
The interventions under investigation include: Oral Vancomycin (DRUG).
Who is sponsoring clinical trial NCT01802073?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01802073 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Sclerosing Cholangitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver Transplantation
RECRUITING · Phase 2
-
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
RECRUITING
-
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
RECRUITING
-
A-LiNK: Improving Outcomes in Autoimmune Liver Disease
RECRUITING
-
Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study
RECRUITING · Early Phase 1
-
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.